Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin in MAFLD
NCT07679542Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of dihydroartemisinin in metabolic associated fatty liver disease (MAFLD), sponsored by Jiangsu Provincial People's Hospital. Started Mar 2026; status: recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07679542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679542.